Phase Ib Trial of Oncolytic Herpes Virus G207 Shows Safety of Multiple Injections and Documents Viral Replication
Open Access
- 1 January 2009
- journal article
- editorial
- Published by Elsevier in Molecular Therapy
- Vol. 17 (1) , 8-9
- https://doi.org/10.1038/mt.2008.275
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBMMolecular Therapy, 2009
- A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant SettingMolecular Therapy, 2004
- HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survivalGene Therapy, 2004
- Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome ProjectJournal of Neurosurgery, 2003
- Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductaseSurgery, 2002
- The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle studyGene Therapy, 2002
- Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Therapy, 2000
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological studyJournal of Neurosurgery, 2000
- Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cellsNature Medicine, 1997